anti-rheumatoid

Ozoralizumab (ATN-103) is a humanized anti-TNFα antibody and a novel TNFα inhibitor.Ozoralizumab binds human serum albumin and can be used to study rheumatoid arthritis.

Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

Golimumab (CNTO-148) is a potent humanized anti-TNFα IgG1κ monoclonal antibody with anti-inflammatory and anticancer activity. It inhibits the production of IL-6 and IL-1β, induces apoptosis, and can be used to prevent inflammation and destruction of cartilage or bone. This makes Golimumab valuable for studying rheumatoid arthritis and cancer.

Eldelumab (BMS-936557) is a humanized anti-IP-10 IgG type 1 monoclonal antibody with inhibitory activity against CXCL10. It has anti-inflammatory properties, selectively binds to CXCL10, and can be used in the study of rheumatoid arthritis, ulcerative colitis, and Crohn's disease.

Olokizumab (CDP-6038) is a humanized anti-IL-6 monoclonal antibody that selectively blocks the final assembly of the IL-6 signaling complex for the study of rheumatoid arthritis (RA).

Itolizumab (Anti-Human CD6 Recombinant Antibody) is a recombinant anti-CD6 monoclonal antibody that targets the extracellular SRCR distal domain 1 of CD6, thereby slowing T cell proliferation and inhibiting pro-inflammatory cytokine production. Itolizumab can be used to study conditions such as psoriasis, rheumatoid arthritis (RA), and COVID-19 disease.

Cabiralizumab (FPA 008), an anti-CSF1R monoclonal antibody (MAb), promotes T cell infiltration and boosts antitumor immune responses. It also prevents osteoclast activation, thereby inhibiting bone destruction, and is utilized in rheumatoid arthritis (RA) research. Additionally, Cabiralizumab can be paired with Nivolumab in lung cancer studies [1] [2].

Vobarilizumab (ALX-0061) is a humanized, specific monoclonal antibody targeting IL-6R and albumin (ALB), consisting of an anti-IL-6R domain and an anti-human albumin domain, used in the study of rheumatoid arthritis and other autoimmune diseases.

Adalimumab beta (ABP-501) is an anti-TNF-α monoclonal antibody used in rheumatoid arthritis (RA) research [1].

Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.

Certolizumab pegol (Certolizumab) is a polyethylene glycolated and humanized anti-TNF-α monoclonal antibody for the study of autoimmune diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).

Theralizumab (TGN1412) is an anti-CD28-targeting monoclonal antibody that directly stimulates T cells. Theralizumab has antitumor activity and is used for the treatment of B-cell chronic lymphocytic leukemia and rheumatoid arthritis.

Nipocalimab (M281) is a fully humanized anti-FcRn monoclonal antibody that can be used to study systemic myasthenia gravis and rheumatoid arthritis.

Zanolimumab (Anti-Human CD4 Recombinant Antibody) is a fully human monoclonal antibody targeting the CD4 molecule, effectively inhibiting T-cell receptor (TCR) signal transduction. It is used in research on rheumatoid arthritis, psoriasis, melanoma, cutaneous, and peripheral T-cell lymphoma [1].

Priliximab (CEN 000029), an anti-CD4 humanized monoclonal antibody, binds to CD4 receptors on T cells, leading to a significant and sustained decrease in circulating CD4+ T cells. This property renders it useful in the study of rheumatoid arthritis (RA) [1].

ABBV-154 is an anti-TNF antibody-drug conjugate (ADC) composed of the humanized antibody Adalimumab linked to a glucocorticoid receptor modulator. It is employed in the research of rheumatoid arthritis, Crohn's disease, and polymyalgia rheumatica.

ABBV-3373 is an anti-TNF antibody-drug conjugate (ADC) composed of the humanized TNF antibody adalimumab and a glucocorticoid receptor agonist. It is designed for use in research related to rheumatoid arthritis.